✓Nov 11 session - Last update: Nov 11, 2026, 5:15 PM ET
🏆Material / Earnings✓High confidence
Source: earnings_events
Changes History →Pre-market · Regular session opens 9:30 AM ET
Last update: Nov 11, 2026, 6:15 PM ETMarket closed·100 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓Nov 11 session - Last update: Nov 11, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: EnerSys (ENS) moved -5.53% from $156.29 to $147.65 on November 11, 2026, after reporting fiscal Q2 2027 results. The company beat adjusted EPS by 0.94% ($3.22 vs. $3.19 estimate) but missed revenue expectations at $949.9 million versus consensus estimates of $967.6–$972.35 million, citing foreign currency translation headwinds. Volume traded at 2.2x the 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor Q3 fiscal 2027 guidance and management commentary from the upcoming earnings conference call for clarity on data center and defense demand trends.
✓Nov 11 session - Last update: Nov 11, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: Lumen Technologies, Inc. (LUMN) moved -6.71% from $4.77 to $4.45 on 2026-11-11. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst directly tied to this move was found in the audit. Volume was near its 5-day average (0.8x), suggesting light trading conditions.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor Lumen's Q3 2026 earnings report on 2027-02-02 for any updates on operational trends or guidance.
✓Nov 11 session - Last update: Nov 11, 2026, 4:44 PM ET
⚡Material / Earnings✓High confidence
What changed: Casella Waste Systems, Inc. (CWST) moved +6.01% from $92.94 to $98.53 on November 11, 2026, after Barclays raised its price target to $109.00 from $104.00 while maintaining an "overweight" rating. The gain followed a post-earnings recovery; CWST had reported Q3 2026 results on November 9 showing EPS of $0.35 versus a $0.41 consensus estimate (a 14.9% miss), but the company's "303 Plan" margin-improvement initiative and activist investor Jana Partners' ongoing involvement renewed confidence.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CWST's next earnings report is scheduled for February 18, 2027, with consensus EPS estimate of $0.27; monitor execution against the 303 Plan and whether margin pressures ease.
✓Nov 11 session - Last update: Nov 11, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: Archrock, Inc. (AROC) moved -6.95% from $28.64 to $26.65 on 2026-11-11, driven by lingering concerns from its third-quarter earnings miss reported on November 2, 2026. Revenue came in at $370.81 million, down 3.04% year-over-year and falling short of the $386.34 million consensus estimate, though EPS of $0.48 beat the $0.45 consensus. Broader sector pressure on natural gas compression and energy infrastructure shares also weighed on sentiment.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Archrock's next earnings are scheduled for 2027-02-23, with consensus EPS estimate of $0.46.
✓Nov 11 session - Last update: Nov 11, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Legence Corp. Class A Common stock (LGN) moved +7.54% from $34.49 to $37.09 on 2026-11-11. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred one day before the company's scheduled earnings report (2026-11-12, consensus EPS estimate $0.57) on volume near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
LGN earnings report due 2026-11-12; compare reported EPS to the $0.57 consensus estimate.
✓Nov 11 session - Last update: Nov 11, 2026, 4:38 PM ET
🛡Material / Earnings✓High confidence
What changed: Pershing Square Inc. (PS) moved -6.08% from $47.40 to $44.52 on 2026-11-11. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume traded near its 5-day average, suggesting the decline occurred without unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor PS earnings on 2026-12-02 and any pre-announcement updates that could clarify the portfolio positioning or performance drivers behind the recent decline.
✓Nov 11 session - Last update: Nov 11, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Alnylam Pharmaceuticals, Inc. (ALNY) moved +5.01% from $152.22 to $159.85 on 2026-11-11. The company announced five-year HELIOS-B data showing sustained AMVUTTRA benefit in ATTR-CM patients, and collaborator Regeneron reported positive first-in-human data for the jointly developed CIDEBsiRNA in MASLD patients.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
ALNY earnings scheduled for 2026-02-11 (consensus EPS estimate $1.72).
✓Nov 11 session - Last update: Nov 11, 2026, 4:38 PM ET
🛡Material / Earnings✓High confidence
What changed: Amphenol Corporation (APH) moved -5.57% from $83.99 to $79.31 on 2026-11-11. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, and the move appears to be technical or driven by broader market factors.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Amphenol's Q3 2026 earnings announcement on 2026-01-27 (consensus EPS estimate $0.81).
✓Nov 11 session - Last update: Nov 11, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Axsome Therapeutics, Inc. (AXSM) moved +5.54% on November 11, 2026, building momentum from multiple catalysts: the company reported Q3 2026 revenue of $259.7 million on November 2, surpassing a $1 billion annualized run rate (52% year-over-year growth) driven by Auvelity sales; management presented at the Guggenheim Healthcare Innovation Conference on November 9; and H.C. Wainwright raised its full-year 2026 EPS estimate from −$4.10 to −$2.71 per share while reiterating a Buy rating on November 11.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Axsome has a May 1, 2027 PDUFA date for AXS-12, and earnings are scheduled for February 22, 2027, with consensus EPS estimate of −$0.05.
✓Nov 11 session - Last update: Nov 11, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Regeneron Pharmaceuticals, Inc. (REGN) moved +6.01% from $904.99 to $959.41 on 2026-11-11 after advancing its CIDEB siRNA experimental therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) to late-stage trials, with Phase I/II data showing a single dose reduced liver fat by up to 80%. The move was also supported by recent analyst price-target increases from Cantor Fitzgerald (to $980) and Truist Securities (to $982), as well as investor focus on the upcoming Eylea HD '036 formulation patent defense at the Patent Trial and Appeal Board.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Regeneron is scheduled to report earnings on 2027-01-28 (consensus EPS estimate $25.39).
✓Nov 11 session - Last update: Nov 11, 2026, 4:38 PM ET
🛡Material / Earnings✓High confidence
What changed: IES Holdings, Inc. (IESC) moved −5.14% from $186.93 to $177.32 on 2026-11-11. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting no unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor IESC's earnings announcement on 2026-11-20 for actual EPS results versus the $2.81 consensus estimate.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisNovember 11, 2026 · 11 min read
CoreWeave (CRWV) Jumps ~25% on a Q3 Beat, Raised Guidance and a $133B Backlog
CoreWeave jumped about 25% to roughly $61 on November 11 after reporting a blowout third quarter the evening before. Revenue rose 168% to about $3.7 billion, above the high end of guidance, and the company raised its full-year outlook while reporting a record $133 billion revenue backlog. For the purest public play on the AI-infrastructure buildout — it rents Nvidia GPUs to the largest AI developers — it was emphatic proof that demand is not the problem. The more important shift was on the other question hanging over the stock: financing. CoreWeave is building a GPU empire on borrowed money, posting a $709 million net loss driven by $846 million of quarterly interest expense, with $14.5 billion of capital spending in the quarter and $37–$39 billion guided for the year. The stock had fallen more than 50% from its high on exactly those worries, so what sparked the rally was management addressing them — a shift toward contract-matched debt and customer prepayments, a lower cost of borrowing, and a path to adjusted profitability by 2028. Still, the balance sheet remains the defining feature: enterprise value near $95 billion against a roughly $33 billion equity value, the gap some $66 billion of debt. Tellingly, even as the stock soared, several analysts cut their price targets hard — from $176 to $100, from $100 to $45 — a sign the demand question is answered but the financing math still has to play out. The move led the AI-infrastructure complex and far outpaced the chip sector, marking it as company-specific.
CRWVRead →
Stock AnalysisNovember 10, 2026 · 11 min read
Hims & Hers (HIMS) Drops ~18% as Q3 Gross Margin Craters on the GLP-1 Shift
Hims & Hers fell about 18% to roughly $18.76 on November 10 — a seven-month low — after third-quarter results that grew revenue 49% to about $890 million but exposed a margin problem underneath. Gross margin collapsed to about 57% from 74% a year earlier, the company swung to a $33 million GAAP net loss (about $0.14 a share, versus a profit expected) even as adjusted EBITDA stayed positive, and it cut its full-year adjusted-EBITDA guidance to roughly $257–$277 million, from $275–$325 million — its third reduction this year. The culprit is the same thing that made HIMS a market darling: weight-loss drugs. As the era of cheap compounded GLP-1 medications wound down, Hims pivoted to selling branded drugs, which are a low-margin, pass-through business, so the mix shift that keeps revenue growing — led by its international rollout — is compressing margins. (A just-announced deal to distribute Eli Lilly's Zepbound, unveiled after the quarter closed, lifted the stock Friday but postdates these results.) Subscribers also disappointed, rising 13% to about 2.79 million but below the roughly 3.04 million expected and down about 100,000 sequentially, with management flagging more weakness. The move was company-specific: telehealth peers were roughly flat, the market barely moved, and Eli Lilly, the drug supplier, actually rose. Wall Street is lukewarm — a Hold consensus, with brokers cutting targets toward the mid-$20s on the print, though still above the price. After a 50%-plus decline the stock trades at under two times sales, which looks cheap only if margins and subscribers stabilize — the very things that just deteriorated.
HIMSRead →
Stock AnalysisNovember 9, 2026 · 12 min read
QXO (QXO) Jumps ~20% as the TopBuild Deal Lifts Q3 Sales 79%
QXO jumped about 20% to roughly $13.90 on November 9 after the building-products distributor released preliminary third-quarter results ahead of its full report. Net sales rose about 79% to $4.9 billion and adjusted EBITDA rose about 85% to $557 million, with the margin edging up to 11.4% — modestly ahead of the roughly $4.85 billion revenue consensus. QXO is the building-products roll-up of Brad Jacobs, who previously built XPO Logistics and United Rentals, and this was its first full quarter including TopBuild, the insulation installer and distributor it bought on July 1 for about $15 billion. So the 79% sales jump is mostly acquired, not organic — the scale of acquisitions landing in the numbers for the first time, though management pointed to improving organic sales trends and firmer pricing on a separate call. What the market rewarded was the margin signal — EBITDA growing faster than sales as a giant deal is absorbed — the clearest early sign the integration is working, against a stock that had fallen roughly 19% over the past year. The caveats are important: these are preliminary, unaudited figures (full results come November 12); the growth is acquisition-driven and the release gave no consolidated organic rate; QXO is still a GAAP loss-maker because of acquisition amortization, interest and deal costs; and the expansion is financed with heavy share issuance (the count is up about 60% in a year) and roughly $7 billion of debt. The move was company-specific — QXO far outpaced building-products peers that rose only mid-single digits. Analysts keep a Strong Buy with an average target near $24, though several had trimmed targets into the quarter. The real verdict waits for the full results.
QXORead →
Stock AnalysisNovember 9, 2026 · 12 min read
Ionis (IONS) Drops ~24% After a Q3 Beat on a Halved TRYNGOLZA Forecast
Ionis Pharmaceuticals fell about 24% to roughly $29.80 on November 9 — and traded as low as $27.75, a fresh 52-week low — even though its third quarter beat: revenue of $243 million topped the roughly $178 million expected, and the GAAP loss of $0.66 a share was narrower than feared. The stock cratered on a guidance cut, not the quarter. Ionis roughly halved its full-year 2026 sales forecast for TRYNGOLZA, its homegrown drug for high triglycerides, to about $50 million from a prior $100–$110 million, citing a slower-than-expected launch ramp (third-quarter TRYNGOLZA sales were just $9 million). Because TRYNGOLZA is the centerpiece of Ionis's transition from a royalty-and-partnership company into one that sells its own drugs, halving its forecast dented the core thesis and pushed the company's path to sustained positive cash flow out about a year, toward 2029. Crucially, this was not a company-wide cut: Ionis left total 2026 revenue guidance unchanged at $875–$900 million, kept cash guidance steady (about $1.9 billion at quarter-end), and reaffirmed its other launched drug, DAWNZERA. The move was clearly company-specific — on the same day the RNA peer Alnylam was flat, the biotech ETF XBI rose about 2% and the S&P 500 rallied. Wall Street mostly treated it as a timing reset, reiterating Buy ratings and leaving an average target near $84, more than double the price. The whole debate is now the slope of the TRYNGOLZA sales line.
IONSRead →
Stock AnalysisOctober 30, 2026 · 12 min read
Reddit (RDDT) Crashes ~30% After a Q3 Beat on a Google AI Search-Traffic Warning
Reddit crashed about 30% to roughly $90.79 on October 30 — a striking reaction, because the quarter itself was strong: revenue of $895 million rose 53% year over year, a clear beat, with net income of $283 million, diluted EPS of $1.40 and adjusted EBITDA of $402 million. The stock cratered on what management said about the future. On the earnings call, CEO Steve Huffman warned that search referrals fell more than a million per week on average in October as Google answers more queries with AI, and that daily active users (around 130 million) could fall a low-double-digit percentage in the fourth quarter if the trend held. Investors also fixed on a 2% year-over-year decline in US daily actives — Reddit's most valuable market, where revenue per user is more than five times the international level — and on fourth-quarter revenue guidance of $1.00–$1.03 billion that came in below expectations; Citizens downgraded the stock before the open. The one bullish counterweight was monetization: revenue per user still jumped 36% globally. The move was company-specific — Reddit's roughly 30% drop was about four times the moves of social peers Snap and Pinterest (each down ~7%), on a day the broad market fell about 2%. After the crash Reddit trades at roughly 14 times forward earnings with about $3 billion of net cash — not expensive for 50%-plus growth, if the growth is durable. The whole debate is whether rising revenue per user can keep outrunning a top of the funnel that AI search is draining.
RDDTRead →
Stock AnalysisOctober 20, 2026 · 10 min read
General Motors (GM) Falls ~8% Despite a Q3 Beat and a $20B Buyback
General Motors fell about 8% to roughly $75.77 on October 20 — a striking reaction, because GM beat on third-quarter earnings, raised its full-year profit outlook and announced a $20 billion buyback. Adjusted earnings of $3.70 a share topped estimates on revenue of about $50 billion, and GM lifted the midpoint of its full-year adjusted-EPS guidance to about $13.25 (from $13.00) and raised its free-cash-flow outlook. The stock fell anyway on what the guidance implied, not the quarter. The full-year outlook implies a softer fourth quarter — only about $2.7 billion of operating profit versus $4.1 billion in the third, as a Silverado/Sierra redesign temporarily cuts truck deliveries by roughly 35,000 units — the raised $13.25 EPS midpoint still landed just below the roughly $13.41 the Street expected, and management flagged about $2 billion of 2026 cost inflation plus a conditional scenario of more in 2027. Two things that look like culprits mostly were not: the 62% drop in EV sales was already known and reflects a distorted 2025 comparison, and tariff costs are now expected near the low end of an existing range. Crucially, GM did not cut its 2027 outlook — it still expects next year to improve if conditions hold. The move was clearly company-specific — Ford fell only about 1%, Stellantis was flat and the S&P 500 rose — so this was a repricing of GM's forward earnings, not an auto-sector sell-off. The valuation captures the tension: GM trades at barely five to six times the forward earnings it guides to, extraordinarily cheap, because the market prices automakers for the downturn, not the peak. A $20 billion buyback into that multiple is powerfully accretive if earnings hold — but whether they hold in 2027 is exactly the question. Analysts keep a Buy consensus and an average target near $104.
GMRead →